The News Feed

Geographic atrophy

Oral Antioxidant and Carotenoid Supplementation Slows Central GA Progression

Post hoc analysis of AREDS data clarifies the regimen’s effect in reducing lesion growth toward the fovea, a finding that could support vision preservation among patients with late-stage disease.
July 18, 2024

Two Studies Give Positive Marks to Pegcetacoplan Therapy for GA

Real-world results show that the drug reduced annual growth rate by about 34%. A clinical trial extension also reported a similar level of efficacy.
May 7, 2024

Similarities and Differences Between Pachychoroid GA and Conventional GA Identified

Understanding these features may help disease diagnosis in Asian populations. Patients with the former subtype were significantly younger, predominantly male and had a slower progression rate.
April 12, 2024

Study Finds Imaging Biomarkers Associated with GA Growth Rate

Progression is positively associated with non-exudative subretinal fluid and hyperreflective material as well as iRORA. It’s negatively associated with retinal pseudocysts and subfoveal choroid thickness.
April 1, 2024

Pachydrusen in AMD Eyes Raises Risk of MNV but Not GA

This is especially the case when macular pigmentary changes are also present, study finds.
March 20, 2024

Investigative GA Drug Fares Poorly in Phase II Trial

After 24 months of treatment with oral minocycline, participants showed no significant decrease in lesion enlargement rate. Mild and moderate AEs were also common.
March 19, 2024

Investigational Subretinal Implant Could Help Restore Vision Loss from GA

Device seeks to mimic photoreceptor function and re-enable retinal neurons. Three subjects gained at least four ETDRS lines in recent tests.
March 12, 2024

Thin Double Layer Sign in the Fovea on OCT Predicts GA

Structural imaging shows the presence of biomarkers associated with the development of foveal atrophy at two years.
February 14, 2024

AMD Genetic Profile Predictive of Early GA Enlargement

ARMS2/HTRA1 is an important risk factor for identifying eyes likely to experience fast lesion progression.
September 19, 2023

New GA Drug from Iveric Bio Approved

Clinical trials show Izervay can slow disease progression with as few as six monthly doses.
August 7, 2023